The US FDA has approved tradipitant, a substance P/neurokinin-1 (NK-1) receptor antagonist, indicated for the prevention of vomiting induced by motion in adults. Clinical evidence In a clinical trial involving more than 680 patients, tradipitant significantly reduced vomiting incidence compared with placebo, with rates of 10.4–19.5% versus 37.7–44.3% during real-world boat travel, representing risk reductions of over 50–70% and demonstrating a favorable safety profile consistent with acute use.
Dosage and administration Available in the form of a capsule The recommended dosage of tradipitant is 85 mg or 170 mg as a single oral dose approximately 60 minutes before an event expected to cause vomiting induced by motion The maximum dosage in a 24-hour period is a single dose of 85 mg or 170 mg Administer on an empty stomach, at least 1 hour prior to or 2 hours after a full meal…
